Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK group to drive "universal access" to prostate LDR (low-dose-rate) brachytherapy:

This article was originally published in Clinica

Executive Summary

The UK National Health Service (NHS) has formally established a prostate brachytherapy advisory group to steer service development in this specialism. The group's main aim will be to "support universal access to low-dose-rate (LDR) brachytherapy in the UK", by: optimising the use of services within radiotherapy centres that currently perform the technique; helping to commission services not available locally; and promoting best practice and evidence-based approaches, sourced in the UK and internationally.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel